Clinical Trial Update: PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluates PF-06863135 as a single agent and in combination with immunomodulatory agents in relapsed/refractory multiple myeloma; the study is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• PF-06863135 (PF-06863135)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2025-03-18